The active ingredient in Arabella’s Wound Care products is a synthetic composition of cations derived from a botanical material found in the ash of red oak bark “QBx” which has been shown to therapeutically down regulate certain matrix metalloproteases (MMPs).
Elevated MMP levels of 2, 3 and 9 are indicative of chronic, non responsive, slow healing wounds. Approximately 80% of chronic wounds display elevated levels of MMPs.
Arabella’s Wound Care products are the only currently available products on the market that are successful in healing chronic, non healing wounds through the down regulation of proteases. These products have shown to be effective in healing chronic wounds in multiple clinical evaluations, with 63% to 94% of wounds demonstrating closure within 45 days.
Arabella has aligned with researchers, developers, medical specialists and others to develop potential life-saving platforms for detecting many diseases and human factor conditions.
Some of these targets identified as high-importance or for which Arabella has a high level of confidence in developing methodologies for early identification include:
1. Type 1 Diabetes
2. Colorectal Cancer
3. Lung Cancer
4. Lactose Intolerance
5. Fructose Intolerance
6. Ovarian Cancer
Other pathogens and cancers may also be possible.
Considerable work has been undertaken and much more is required before tests are
available to meet Arabella’s expectations in respect to these conditions.
